SAN FRANCISCO, Nov. 9, 2010 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc., a leader in innovative biologics, announced today that Julia P. Gregory, president and chief executive officer, and Dr. Michael Kavanaugh, M.D., senior vice president and head of research and development, will be presenting at the Lazard Capital Markets 7th Annual Healthcare Conference at the St. Regis Hotel in New York, New York. Their presentation will take place on Tuesday, November 16, 2010 at 9:25 am Eastern Standard Time in the Watteau room. Ms. Gregory and Dr. Kavanaugh, M.D. will present an overview of FivePrime, discuss the company's clinical and preclinical development programs and its recent collaboration with GlaxoSmithKline. A live webcast will also be available, which can be accessed 90 days following the conference by visiting .
Five Prime Therapeutics, Inc. is a clinical-stage, privately-held, biotechnology company discovering and developing innovative protein and antibody therapeutics. FivePrime is currently testing FP-1039, a first-in-class biologic, in a Phase I study for patients with solid tumors and will soon begin a Phase II trial in endometrial cancer. Using its novel high-tech discovery platform, FivePrime is building a strong product pipeline in oncology, immunology and metabolic diseases. Its proprietary platform mines FivePrime's library of all the secreted and extracellular human proteins to screen for medically relevant new therapeutic protein and antibody drugs. FivePrime is collaborating with Pfizer, Inc. in the fields of oncology and diabetes and GlaxoSmithKline for skeletal muscle disorders. For more information, visit .
The Five Prime Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8029
CONTACT: Five Prime Therapeutics, Inc. Debbie Tobin 415-365-5721 Debbie.Tobin@fiveprime.com Two Corporate Drive South San Francisco, CA 94080